Ruth Oâ€™Regan, MD

Articles by Ruth Oâ€™Regan, MD

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

ByElisavet Paplomata, MD,Ruth Oâ€™Regan, MD

March 27th 2015

The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.

Latest Updated Articles

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer
March 27th 2015

Ruth Oâ€™Regan, MD

Articles by Ruth Oâ€™Regan, MD

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

Latest Updated Articles

Trending on OncLive

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma

NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer

CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care